HR-19042

This is a single-center, randomized, open-label, three-period, dual Latin square crossover study.
Primary Objective：
1. To evaluate the oral relative bioavailability of HR19042 Capsules compared with budesonide delayed-release capsules (Tarpeyo®) and budesonide enteric-coated capsules (Budenofalk®).
Secondary Objective
2. To assess safety following administration.